Pfizer Says Early Studies of Potential Coronavirus Treatment Show Promise - COVID-19 Clinical Trial
Breaking News | COVID-19

Pfizer Says Early Studies of Potential Coronavirus Treatment Show Promise

U.S. drugmaker Pfizer Inc said on Thursday that early data has helped it identify a drug candidate with the potential to help treat patients infected with the novel coronavirus. It also said it plans to support studies to determine whether existing Pfizer medicines, including its rheumatoid arthritis drug Xeljanz, may provide benefits for those struggling with the COVID-19 respiratory illness caused by the coronavirus. 


Second US study for COVID-19 Vaccine Uses Skin-deep Shots 

Researchers have opened another safety test of an experimental COVID-19 vaccine, this one using a skin-deep shot instead of the usual deeper jab. These early-stage studies are a first step to see if a vaccine appears safe enough for larger tests needed to prove whether it will protect. Even if the research goes well, it is expected to take more than a year before any vaccine could be widely available. 


UPMC Launches ‘Learning While Doing’ Clinical Trial of COVID-19 Vaccine 

The University of Pittsburgh School of Medicine launched Thursday a novel clinical trial based on a key debate circling the coronavirus pandemic: When to use experimental drugs on patients? If new drugs need to be tested, they are rolled into the platform as study amendments, rather than tested in separate free-standing trials, according to the release. All participants will receive the current standard of care, and most also will receive one, two or three of the experimental treatment options 

Share this:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on reddit
Reddit
Share on email
Email
Scroll to Top

Your choice regarding cookies on this site

We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

For more detailed information on the cookies we use, please check our Privacy Policy.

By continuing to access this website you are giving us consent to collect cookies.

Want to stay informed?

With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.